Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197019 | 0.87 | EPHX2 (0.51) | EPHX2TSHRMAPK14CYP3A4LMNA | |
| SCHEMBL13876720 | 0.86 | EPHX2 (0.62) | EPHX2MAPK14CYP3A4 | |
| SCHEMBL4193143 | 0.83 | EPHX2 (0.62) | EPHX2TSHRLMNAMAPK1NLRP1 | |
| SCHEMBL4188533 | 0.82 | EPHX2 (0.59) | EPHX2TSHRLMNAMAPK1NLRP1 | |
| SCHEMBL4197131 | 0.82 | EPHX2 (0.60) | EPHX2TSHRLMNAMAPK1NLRP1 | |
| SCHEMBL4188523 | 0.82 | EPHX2 (0.66) | EPHX2TSHRLMNAMAPK1NLRP1 | |
| SCHEMBL4185352 | 0.79 | EPHX2 (0.68) | EPHX2TSHRLMNAMAPK1NLRP1 | |
| SCHEMBL13876445 | 0.79 | EPHX2 (0.66) | EPHX2MAPK14CYP3A4ROCK2ROCK1 | |
| SCHEMBL13876505 | 0.79 | EPHX2 (0.60) | EPHX2MAPK8 | |
| SCHEMBL4197060 | 0.78 | EPHX2 (0.72) | EPHX2TSHRLMNAMAPK1NLRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2007098352-A2 | SUBSTITUTED PYRIDINEAMIDE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885TSHR 4438/4885MAPK14 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.